Skip to main content
Sign In
 

Clinical Trials

Volunteer to Be Part of a Research Study


Page through all School of Medicine clinical and research trials below. There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 111.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 111.
Diabetic Male and Female Volunteers Needed for Exercise Research Study
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
10/24/2014
Trouble Controlling your Type 2 Diabetes?
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
10/24/2014
Project Safe - THE IMPACT OF MEDICAL MARIJUANA IN METROPOLITAN DENVER
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
10/24/2014
Persons with active, moderate to severe ulcerative colitis needed
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
10/24/2014
3D Gait Analysis Participants Needed
Research study investigating the coordination of walking
Subject with Spastic Cerebral Palsy Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Retrospective gait data must contain a complete lower body marker set and valid kinetic data. ● Only gait data trials of the subject walking unassisted will be used. ● Diagnosis of spastic cerebral palsy. ● Exhibits either stiff knee gait pattern, characterized by insufficient and delayed peak knee flexion during swing (less than 45), or crouch gait pattern, characterized by excessive hip flexion and knee flexion (greater than 30 throughout stance). Cerebellar Ataxic Gait Subject Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Diagnosis of either Friedreich's or spinocerebellar ataxia. Subject with Lower Limb Amputation Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Has been using the prosthetic limb for at least 6 months for independent ambulation prior to gait analysis at CGMA. ● Below knee or above knee amputation.
10/24/2014
Would you like to participate in a study to improve the understanding of how emotions and symptom distress affect adherence to hormonal therapy in breast cancer?
The purpose of this study is to understand how emotional factors and symptom distress affect adherence to hormonal therapy in women that have completed all other treatment for breast cancer.   
Women Breast Cancer Survivor Age 21-70 years old Within 24 months of starting hormonal therapy: Aromatase Inhibitors or Tamoxifen (Aromatase Inhibitors, Exemestane (aromasin), Letrolzole (Femara), Anastrozole (Arimidex).
10/24/2014
Do you spend most of your day sitting?
The Anschutz Health & Wellness Center is seeking participants for a new research project to determine if exercise performed throughout the day is more energizing compared to exercise performed in the morning or if you do not exercise.
Participants must meet the following criteria: - Sedentary - Between the ages of 25 - 50 - BMI between 18.5 and 29.9 kg/m^2 - Non-smoker
10/24/2014
Pharmacokinetics Research Study of Nontuberculous Mycobacteria Antibiotics in HEALTHY people and in people with CYSTIC FIBROSIS
We are conducting a research study to test if levels of antibiotics used to treat nontuberculous mycobacteria infections are different between people with and without cystic fibrosis. The goal of our study is to provide recommendations for treatment of CF patients with lung disease due to nontuberculous mycobacterial infection.
Teenagers and adults who are either healthy or who have cystic fibrosis and are 16 to 45 years old may be eligible to participate in this study.
10/24/2014
Have the Flu? Living with a chronic medical condition, too?
Influenza (the flu) can be life-threatening. Approximately 24,000 people in the United States die each year of this disease. We are conducting a study to determine whether treating patients with a combination of several drugs instead of just one helps them to get better faster.
You qualify for our study if you: •Have been diagnosed with the flu •Are at least 18 years of age •Have an existing medical condition that puts you at increased risk for complications from the flu—conditions such as diabetes; heart, lung, and kidney disease; COPD; and asthma
10/24/2014
Women needed for Research Study
To examine how BMI affects fertility
Healthy women 18-39 with a BMI greater than 30 with regular menstrual cycles and not pregnant or trying to conceive and not on any hormones (like birth control).  Must be willing to collect your first morning urine daily for one menstrual cycle and provide blood samples.
10/23/2014
Are you taking medications for diabetes and resulting kidney complications?
To evaluate a new investigational drug for people with Type 2 diabetes and kidney disease.
Person 18+ who are not of child bearing potential (f female) with type 2 diabetes and currently taking medication for kidney disease. You must be able to attend at least 6 office visits over 16 weeks.
10/23/2014
Apoyo con Cariño: Improving Palliative Care for Latinos with Cancer
We want to understand if a patient navigator can help Latino patients and their family caregivers deal with cancer. Our project hopes to improve palliative or comfort care to patients with advanced cancer. The goal is to prevent or relieve suffering for people facing serious illness. Research is needed to find out if a patient navigator can help patients and family caregivers.
Adults (18 years and older) who self-identify as Latino and have Stage III-IV cancer.
10/23/2014
Seeking Adults with NO History of Eczema, Allergies or Asthma
The purpose of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Males and females between 18 and 64years of age with no history of Allergies, Eczema, or Asthma
10/23/2014
SPIROMICS-Subpopulations and Intermediate Outcome Measures in COPD Study
To identify subpopulations of COPD patients in order to develop newer and more effective treatments and to clearly define measureable end points so that treatment effects may be accurately assessed in a shorter period of time.
Be willing to undergo study procedures Be between the age of 40 and 80 years old Have smoked fewer than one pack of cigarettes per day for one year OR have smoked more than one pack of cigarettes per day for 20 years
10/23/2014
Psychiatric Medication Study
We are looking for volunteers to participate in a research study investigating how psychiatric medications are processed in people who are diagnosed with HIV-1 compared to subjects who are on psychiatric medications who are HIV-negative. You can participate in this study if you are HIV negative and taking certain psychiatric medications.
To Qualify: Must between the ages of  2 to <25 years; Be HIV-Negative; On a steady dose of Psychiatric Medication (Celexa, Lexapro, Risperdal, Zoloft, Prozac, Paxil or generic equivalents)
10/23/2014
HEALTHY MEN AND WOMEN 60-85 YEARS OLD Wanted to participate in a research study
To test whether interrupting prolonged sitting with short bouts of moderate intensity walking can improve health
We are looking for men and women who:  Are age 60-85 years old  Healthy – no diagnosed disease  Not on glucose lowering medication  Do not participate in regular exercise  Ambulatory – able to walk without assistance  Are non-smokers
10/23/2014
Healthy Female Adolescents Needed!!!
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
10/23/2014
Are you watching your weight?
We are seeking women interested in participating in a research study at the Anschutz Health and Wellness Center. We aim to test whether consuming a daily sweet beverage impacts food intake throughout the day.
You may qualify for this research study if you: • Are a female between 18 – 65 years old and in generally good health • Have intentionally lost weight in the last year and are seeking to maintain that weight loss Or have unintentionally gained weight in the last year and are concerned about it • Have not been diagnosed with type 1 or type 2 diabetes • Can participate in weekly study visits at the Anschutz Medical Campus for one month
10/23/2014
Healthy Females needed! Ages 11 to 29
For brain imaging research study on how the brain works with we taste sweets or receive money.  Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 29 who are right-handed, free of medication with no serious medical condition or permanent metal implants or braces/retainers.
10/22/2014
We are looking for Healthy Women to participate in a research study on.....Females, Aging, Metabolism, and Exercise (FAME)
To examine the role that female sex hormones play in metabolism, energy expenditure, physical activity and chronic disease.
Healthy women 40-60 who have regular menstrual cycles and using no hormonal contraceptives
10/22/2014
Diabetes?
To evaluate study medication for Type 2 Diabetes.
Person 18+ diagnosed with Type 2 Diabetes
10/22/2014
Do you have Diabetes?
To find the best combination drug treatment for type 2 diabetes
Persons who have had diabetes for less than 5 years and metformin is the only diabetes medication you are taking.
10/22/2014
Type 1 Diabetes Research Study
To study the effects of an FDA-approved medication on metabolism and blood vessel function.
Person 25-50 with type 1 diabetes who exercise vigorously less than four times per week and have normal blood pressure
10/22/2014
Male and Female Volunteers with Type 2 Diabetes Needed for a Research Study
To look at the effects of exenatide (a diabetes medication) on exercise capacity in people with type 2 diabetes.
Persons 45-70 who have type 2 diabetes controlled with oral medications, do not smoke and exercise one hour or less per week.
10/22/2014
CHILDHOOD and ADOLESCENT MIGRAINE PREVENTION STUDY
to test two medicines for migraine prevention in children and teens. We want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency.
Children 8-17 who have migraine headaches
10/22/2014
Just received VARIVAX, the chickenpox vaccine?
Research study looking at the immune response to chickenpox vaccine
Age 12 months to 50 years; able to enroll in study within 10 days of vaccination.
10/22/2014
Healthy Women Needed for Cardiovascular Research Study
The purpose of this study is to investigate how the menopause transition and the loss of estrogen impacts the health and function of arteries in women.
- Premenopausal women 18-49 years, Perimenopausal women 40-55 years and Postmenopausal women 45-70 years - Non-smokers - Volunteers should NOT be taking Birth Control or Hormone Replacement Therapy (HRT) or exercising vigorously more than 2 days per week.
10/22/2014
Do You Use a Wood Burning Stove?
This study will be evaluating the effects that a wood burning stove has on the quality of the indoor air in your home and your respiratory health.
People who use wood burning stoves for cooking or to heat their homes in the winter.
10/22/2014
We are seeking physically active men for a research study: PTH and Calcium Response to Exercise (PACE)
Determine whether preventing the decrease in blood calcium levels prevents an increase in parathyroid hormone, or PTH, which causes bone to release calcium.
 Men in generally good health, aged 18-45 years  Regularly cycle for exercise and can ride for an hour at a vigorous intensity  Not taking medication for osteoporosis  No history of asthma
10/22/2014
Research investigating the influence of a Monopoly Game on Subtle Behaviors
This research study plans to learn more about how a stressful game of monopoly will influence subtle behaviors.
To qualify for the study you must be: Between the ages 19-25 Consider yourself Hispanic/Latino Born in the United States Be a non-smoker Have played the game Monopoly before
10/22/2014

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA. Sponsor Protocol No. WO29074. WIRB Protocol No. 20131502
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM). Sponsor Protocol No. 109MS401. WIRB Protocol No. 20140071
Schreiner, Teri13-2897
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome. Sponsor Protocol No. Neu-2566-FXS-001. WIRB Protocol No. 20132053
Tartaglia, Nicole13-3117
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected with Human Immunodeficiency Virus (HIV). Sponsor Protocol No. AI444216. WIRB Protocol No. 20140021
Campbell, Thomas13-3250
A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception. Sponsor Protocol No. 16973. WIRB Protocol No. 20140151
Tocce, Kristina13-3258
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079